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AbstrACt
background The cardiovascular risk of obesity is 
potentially increased by arterial stiffness.
Objective To assess the relationship of adiposity 
measures with arterial stiffness in Caucasian adults with 
intermediate cardiovascular risk.
setting Six Spanish health centres.
Participants We enrolled 2354 adults (age range, 35–
74 years; mean age, 61.4±7.7 years, 61.9% male).
Methods This is a cross-sectional study that analyses data 
from the baseline visit of the improving interMediAte RisK 
management (MARK) study. The main outcome variables 
were body mass index (BMI), waist-to-height ratio (WHtR), 
Clínica Universidad de Navarra-body adiposity estimation 
(CUN-BAE) body fat percentage and body roundness index 
(BRI). Vascular function was assessed by the cardio-ankle 
vascular index (CAVI) with the VaSera device; brachial-
ankle pulse wave velocity (baPWV) was determined using a 
validated equation.
results The mean adiposity measures were a BMI of 
29.2±4.4, WHtR of 0.61±0.07, CUN-BAE of 35.7±1.7 
and BRI of 5.8±1.7. The mean stiffness measures were 
a CAVI of 8.8±1.2 and baPWV of 14.9±2.5. In multiple 
linear regression analyses, all adiposity measures were 
negatively associated with CAVI and baPWV (p<0.01 for 
all) after adjustment for possible factors of confusion. 
The proportion of CAVI variability via the adiposity 
measures were 5.5% for BMI, 5.8% for CUN-BAE, 
3.8% for WHtR and 3.7% for BRI. These were higher 
among diabetic, obese, younger (≤62 years) and non-
hypertensive subjects who had similar activity and 
sedentary profiles.
Conclusions Adiposity measures are negatively 
associated with arterial stiffness measures. The 
percentage of variation in CAVI explained by its relation 
to the different measures of adiposity ranges from 
5.8% (CUN-BAE) to 3.7% (BRI). In the case of baPWV, it 
oscillates between 0.7% (CUN-BAE and BMI) and 0.1% 
(WHtR).
trial registration number NCT01428934.
IntrOduCtIOn
Obesity causes increased morbidity and 
mortality both globally and via cardiovascular 
diseases.1 However, the pathophysiolog-
ical mechanisms that explain how obesity 
increases cardiovascular diseases complemen-
tary to classic risk factors are not well clari-
fied.2 It has been suggested that increased 
arterial stiffness is the pathological pathway 
through which obesity increases cardiovas-
cular disease regardless of other classical risk 
factors.3 We now know that the arterial stiff-
ness measured with the brachial-ankle pulse 
wave velocity (baPWV) has independent 
capacity to predict coronary arteriosclerosis 
and mortality in the general population4 
and in subjects with diabetes.5 6 Similarly, the 
cardio-ankle vascular index (CAVI) is related 
to arteriosclerotic disease in carotid and coro-
nary arteries7–9 and can predict new cardio-
vascular events in obese subjects.10 However, 
the association between adiposity and arterial 
stiffness remains controversial. In this respect, 
there are studies that show that the body mass 
index (BMI) has an independent relationship 
strengths and limitations of this study
 ► This is the first study to investigate the association 
between adiposity measures using a cardio-ankle 
vascular index (CAVI) with brachial-ankle pulse 
wave velocity (baPWV) in Caucasian adults with 
intermediate cardiovascular risk.
 ► All adiposity measures were negatively associated 
with CAVI and baPWV.
 ► The arterial stiffness variability was better explained 
for body mass index and Clínica Universidad de 
Navarra-body adiposity estimation as well as when 
CAVI was used as a measure of stiffness rather than 
baPWV.
 ► The most important limitation of this study 
is its transversal design, which prevents the 
establishment of causal relationships. It is also 
limited by the direction of influence of adiposity 
measures on arterial stiffness.
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with arterial stiffness in the general population3 11 and in 
patients with diabetes.12 13 However, other research has 
not yet found this association,14 or the association disap-
peared after adjusting for potential confounders,13 or it 
showed a negative association.15 16
Other studies suggested a stronger correlation of 
measures in central or visceral adiposity than measures 
of general adiposity with arterial stiffness in the general 
population3 17–20 in patients with diabetes13 and patients 
with hypertension.21 Finally, the Whitehall II Cohort 
study22 showed that all measures of general adiposity, 
central adiposity and body fat percentage (BF%) were 
predictors of accelerated arterial stiffness in adults. In this 
context, the analysis of the relationship between arterial 
stiffness and different measures of adiposity can explain 
the role of obesity in cardiovascular disease.
Our study was designed bearing in mind that cardio-
vascular events occur more frequently in subjects with 
intermediate cardiovascular risk23 and that there is are 
a lack of studies analysing the relationship of different 
adiposity measures with arterial stiffness in these subjects. 
The principal aim of this study was to analyse the rela-
tionship between adiposity measures and arterial stiffness 
in Caucasian adults with intermediate cardiovascular risk. 
The secondary aim was to investigate the changes between 
the associations of adiposity measures with distinct arte-
rial stiffness markers.
MethOds
study design
The results presented here correspond to a subanal-
ysis of the MARK study to data collected at the base-
line visit. The characteristics and form of selection 
of the subjects—as well as the methodology of the 
measurements made in the subjects included in the 
improving interMediAte RisK management (MARK) study 
(NCT01428934)—has been published in the same 
protocol24 and in previous publications from the MARK 
study group.25 26 The MARK study was a cross-sectional 
study whose main objective was to evaluate whether 
the ankle-brachial index (ABI), the CAVI, postprandial 
glucose, glycosylated haemoglobin, pressure arterial 
self-measurement and the presence of comorbidities are 
independently associated with the incidence of vascular 
events and whether these measures can improve the 
predictive capacity of the current risk equations. The 
second part is a follow-up of 5 years and 10 years to esti-
mate cardiovascular morbidity and mortality.24
study population
The population was enrolled at six primary care centres 
from different regions of Spain. The data collection was 
from July 2011 to June 2013. The study included subjects 
aged 35 and 74 years who had intermediate cardiovas-
cular risk. It was defined as coronary risk between 5% and 
15% at 10 years according to the Framingham-adapted 
risk equation27: cardiovascular mortality risk between 1% 
and 5% at 10 years according to the SCORE equation28 
or a moderate risk according to the European Society of 
Hypertension guidelines for the management of arterial 
hypertension.29
The exclusion criteria were terminal illness, institution-
alisation at the appointment time or a personal history 
of atherosclerotic disease registered in his/her electronic 
clinical history. This study analysed 2354 of the 2495 
subjects recruited in the MARK study. In this analysis, we 
excluded 141 individuals with ABI ≤0.9 (n=99) or whose 
CAVI (n=16), baPWV (n=12) and WC (n=14) measure-
ments were incomplete (figure 1).
Anthropometric measurements
Weight was achieved using a certified electronic scale 
(Seca 770, medical scale and measurement systems, 
Birmingham, UK) after adequate calibration (preci-
sion ±0.1 kg). The subjects’ weights were rounded to the 
nearest 100 g. Height was achieved using a stadiometer 
(Seca 222). We used the average of two measurements of 
body weight and height. To calculate the BMI, we used 
the following formula: BMI=weight (kg)/height squared 
(m2). The waist circumference was measured according 
to the 2007 recommendations of the Spanish Society for 
the Study of Obesity.30 The measurements were executed 
with the subjects standing, wearing no shoes and in light 
clothing. To calculate waist-to-height ratio (WHtR), we 
use the following formula: WHtR=waist circumference 
(cm)/height (cm).31 32
The BF% was calculated according to the Clínica 
Universidad de Navarra-body adiposity estimator (CUN-
BAE) using the recommendations of Gómez-Ambrosi 
et al33: BF%=−44.988+ (0.503 × age) + (10.689 × sex) + 
(3.172 × BMI) − (0.026 × BMI2 + (0.181 × BMI × sex) − 
(0.02 BMI × age) − (0.005 × BMI2 × sex) + (0.00021×BMI2 
× age). Here, male=0 and female=1 for sex.
Figure 1 Flow chart. MARK substudy. ABI, ankle-brachial 
index; baPWV, brachial-ankle pulse wave velocity; CAVI, 
cardio-ankle vascular index; WC, waist circumference.
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The body roundness index (BRI) was calculated 
using the following formula: BRI=364.2–365.5 × √
1−
 (WC/(2pi))2
(0.5 height)2
.34 The BRI can estimate the percentage 
of body fat and visceral adipose tissue.
CAVI and baPWV
The device VaSera VS-1500 device (Fukuda Denshi) 
was used to measure the CAVI.35 36 The CAVI 
values were calculated by estimating the stiff-
ness parameter β using the following equation: 
β = 2ρ× 1/(Ps− Pd)× ln (Ps/Pd)× PWV2, where ρ is blood 
density, Ps and Pd are SBP and DBP in mm Hg and 
PWV was measured between the aortic valve and the 
ankle.37 The mean coefficient of variation of CAVI 
values was less than 5% indicating that it is a repro-
ducible measure facilitating clinical use.36
The baPWV was estimated using the equation 
baPWV=(0.5934 × height (cm) + 14.4724)/tba (where 
tba is the time interval between the arm and ankle 
waves).38
One hour before the measurements, subjects were 
fasted from smoking and physical exercise. The measure-
ments were performed after 10 min in supine decubitus 
and with stable temperatures.
definition of hypertension, type 2 diabetes mellitus and 
dyslipidaemia
The subjects were diagnosed with hypertension 
following the criteria of the European Society of Hyper-
tension and European Society of Cardiology (ESC) 
guidelines (values ≥140 mm Hg systolic blood pressure 
(SBP) and/or ≥90 mm Hg diastolic blood pressure 
(DBP) or the presence of antihypertensive treatment)29 
or if they were previously diagnosed with hypertension. 
Type 2 diabetes mellitus was diagnosed following the 
criteria of the American Diabetes Association: presence 
of HbA1c ≥6.5% or fasting plasma glucose ≥126 mg/
dL or 2-hour plasma glucose ≥200 mg/dL during an 
oral glucose tolerance test or in a patient with classic 
symptoms of hyperglycaemia or hyperglycaemic crisis, a 
random plasma glucose ≥200 mg/dL or the presence of 
antidiabetic treatment.39 Subjects were also included if 
they had been previously diagnosed with type 2 diabetes 
mellitus. Dyslipidaemia was defined if they were treated 
with lipid-lowering drugs or had altered low-density 
lipoprotein (LDL) ≥130 mg/dL, high-density lipopro-
tein (HDL) ≤45 mg/dL in men and ≤55 in women and 
triglyceride (TG) ≥150 mg/dL as established by the ESC 
and the European Atherosclerosis Society 2011.40
Office or clinical blood pressure
We performed three measurements of SBP and DBP 
using a validated OMRON model M10-IT sphygmo-
manometer (Omron Health Care, Kyoto, Japan). The 
blood pressure was taken following the recommenda-
tions of the European Society of Hypertension.41 The 
measure was the average of the last two measurements.
Lifestyles
Tobacco
Data were collected whether the subjects smoked or not. 
We defined smokers as those who currently smoke or who 
have not smoked for a year.24
Leisure time physical activity (LTPA)
LTPA was measured with the Minnesota LTPA Question-
naire42 validated in Spanish population in males and 
females.43 44 The questionnaire was collected by previously 
trained interviewers, and the time spent in the registry 
was between 10 and 20 min per subject. Information was 
collected about the type, duration and frequency of phys-
ical activity (PA) for each subject during the previous year. 
Each PA was assigned a code according to its intensity. 
This code is based on the quotient obtained by dividing 
the metabolic rate during the practice of BP between the 
basal metabolic rate (MET).45 We assume that 1 MET 
equals 1 kcal/min of energy expenditure. Thus, we calcu-
lated the total energy expenditure during the free time 
of PA (EEPAtotal) in kilocalories per week. By considering 
the intensity code of the PA, we could measure the energy 
expenditure in PA (EEPA) according to the classifica-
tion of the PA performed (intense, moderate or light) 
as follows: we considered light intensity PA at <4 MET 
such as walking (EEPAlight). Moderate intensity PA was 
4–5.5 METs such as brisk walking (EEPAmoderate). Intense 
intensity PA was greater than or equal to 6 METs such as 
jogging (EEPAintense). Therefore, in each individual, the: 
EEPAtotal=EEPAlight + EEPAmoderate + EEPAintense.
46
Following the recommendations of the American Heart 
Association,47 we considered the subjects sedentary when 
they did not comply with the recommendations of prac-
ticing moderate intensity PA for a minimum of 30 min 5 
days per week (EEPA moderate <675 kcal/week) or high-in-
tensity aerobic PA practice for a minimum of 20 min on 3 
days each week (EEPAintense <420 kcal/week).
46
Laboratory determinations
After 12 hours of fasting from eating and smoking, a 
blood test was performed at the health centre between 
08:00 and 09:00 hours. Plasma glucose, HDL cholesterol 
concentrations and TG concentrations were measured 
using standard enzymatic automated methods. The Frie-
dewald equation was used to calculate LDL cholesterol. 
The atherogenic index was calculated as total choles-
terol/HDL cholesterol. The researchers who performed 
the assays different tests were blinded to the clinical data 
of the participants. The different tests were carried out 
within a maximum period of 10 days.
Data analysis
Descriptive statistics were expressed as the mean±SD 
for continuous variables or number (%) for categor-
ical variables. The χ2 test or the Fisher’s exact test anal-
ysed the association between independent categorical 
variables. Quantitative variables were compared using 
Student’s t-test. Pearson’s correlation coefficient was used 
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to estimate the relationship of the adiposity measures to 
CAVI and baPWV. We used Steiger’s Z statistics to test 
the significance of the difference between correlation 
coefficients.48
Four different multiple linear regression models were 
used to study the associations of each adiposity measure 
with CAVI, and four other models were used with baPWV. 
The CAVI and baPWV were the dependent variables, and 
the adiposity measures were the independent variables in 
each model. All models were adjusted for age (years), sex 
(0=male and 1 = female), SBP, smoking status (0=no and 
1=yes), atherogenic index, HbA1c and METs/min/week. 
The explanatory capacity of the model was measured 
by R2, and the proportion attributed to each variable 
was estimated by the change in R2. The analysis was also 
performed via age groups, diagnosis of diabetes, hyper-
tension and obesity.
Analysis of covariance models were used to test the 
differences in the mean values of CAVI and baPWV with 
the quartiles of the four adiposity measures after adjusting 
for the confounding variables that were used in regres-
sion analysis. Pairwise post hoc comparisons were studied 
using the Bonferroni test. Data were evaluated using 
SPSS Statistics for Windows V.23.0. We defined significant 
differences at p<0.05.
Ethics statement
Before inclusion, all participants were informed about 
the objectives, tests to be performed and the need to 
sign the consent to participate in the study. The study 
was approved by the independent ethics committee 
of the Primary Care Research Institute Jordi Gol, the 
Health Care Area of Salamanca and Palma of Mallorca. 
The study followed the recommendations of the Declara-
tion of Helsinki.49 The confidentiality of the information 
provided by participants was ensured by complying with 
the rules established by Spanish Organic Law 15/1999 of 
13 December on the Protection of Personal Data.
resuLts
Anthropometric measures, clinical characteristics and 
vascular function measures of the subjects are presented 
in table 1. The mean age of the patients was 61.4±7.7 
years, and 61.9% were male. Male subjects constituted a 
higher percentage of smokers (31.5 vs 22.7) and hyper-
tension (80.1 vs 75.4) compared with females. However, 
females had a higher prevalence of obesity (40.4 vs 33.4), 
sedentariness (53.7 vs 37.0), dyslipidaemia (73.1 vs 63.6) 
and diabetes (36.5 vs 31.8) relative to men. The mean 
value of CAVI was 8.8±1.2 (8.9 in males and 8.6 in females, 
p<0.001). The mean baPWV was 14.9±2.5 (14.8 in males 
and 15.0 in females). All of the adiposity measures except 
for waist circumference were higher in women than men.
Pearson’s correlation coefficient results between the 
adiposity measures and the vascular function parameters 
are shown in table 2. All adiposity measures were nega-
tively correlated with CAVI, and this correlation increases 
after adjusting for age, sex and SBP. The correlation 
between CAVI and baPWV was r=0.745 (p<0.001). We 
found differences in correlation coefficients between 
CAVI, baPWV and measures of adiposity (p<0.001 in all 
cases).
The online supplementary figure shows that the esti-
mated marginal means of CAVI (A) and baPWV (B) by 
quartiles of the different adiposity measures. After adjust-
ment for the variables used in the multiple linear regres-
sion analysis, the mean CAVI values decreased as the 
quartiles of the four adiposity measurements increased 
(p<0.05). However, the same is not true of baPWV with 
WHtR and BRI (p>0.05).
In the multiple linear regression analysis, CAVI and 
baPWV showed negative associations with all adiposity 
measures (p<0.01 for all) after adjustment for age, sex, 
SBP, smoking, atherogenic index, HbA1c and METs/
min/week (table 3). The proportion of CAVI variability 
that can be attributed to the variation in the adiposity 
measures was 5.5% for BMI, 5.8% for CUN-BAE, 3.8% for 
WHtR and 3.7% for BRI. For baPWV, the variability by the 
measures of adiposity were 0.7% for BMI and CUN-BAE, 
0.1% for WHtR and 0.2 for BRI. The association between 
adiposity measurements and CAVI revealed a standardised 
β between −0.450 (CUN-BAE) and −0.221 (WHtR). In the 
case of baPWV, the values oscillate between −0.152 (CUN-
BAE) and −0.044 (WHtR).
In the multiple linear regression analysis by subgroup, 
the proportion of CAVI variability by adiposity measures 
was higher among diabetics, the obese, non-hypertensive, 
and subjects 62 years of age or younger; it was similar in 
active and sedentary people (table 4).
dIsCussIOn
This study showed that adiposity measures have a nega-
tive association with arterial stiffness, especially CAVI. 
BMI and CUN-BAE have the highest coefficient of deter-
mination. We found a negative association of different 
adiposity measures with CAVI and baPWV after adjust-
ment for other variables of confusion.
In this study, the mean value of CAVI was higher in 
males, which concurs with published data indicating that 
CAVI increases linearly with age. The values of CAVI are 
higher in men than in women (approximately 0.2, which 
is equivalent to 4–5 years old).22 50 We found no differ-
ences in the mean values of baPWV between sexes, which 
is consistent with data published by Tomiyama et al,51 
who showed that the effect of age on baPWV is different 
according to sex. Females have a higher arterial stiffness 
than prepubertal males—this increases after menopause. 
Men, however, experience a linear increase in arterial 
stiffness from puberty. This suggests that the large arteries 
of females are intrinsically more rigid than those in men. 
However, in women in reproductive age, the effects are 
offset by sex hormones.52 53
This negative association with CAVI has already been 
described in previous studies. BMI shows a negative 
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association in children,54 and in patients with hyperten-
sion and in subjects with diabetes in Ghana.55 Similarly, 
the waist circumference has a negative relationship in 
subjects with metabolic syndrome.26 56
However, other authors have described a positive asso-
ciation of different adiposity measures with the β-stiff-
ness parameter, but after adjustment for age and other 
possible confounding factors, the association remained 
for only men with type 2 diabetes mellitus.57 Other studies 
showed no association between BMI and CAVI.58
Studies analysing the association of adiposity measures 
with baPWV have also been performed mainly in Eastern 
populations and have assessed the association between 
BMI and waist circumference as measures of adiposity. 
The results are controversial with some finding a nega-
tive association with BMI51 and with waist circumference 
in men or only in women.59 60 However, other studies 
showed a positive correlation with BMI and waist circum-
ference.61 One study analysed the association of different 
adiposity parameters with baPWV in middle-aged adults 
and found a positive association with waist circumference 
and visceral fat but not with BF%.62
The results are also not consistent in studies that 
used the carotid-femoral pulse wave velocity (cfPWV) 
Table 1 General characteristics of all the sample and by gender
Variables Global (n=2354) Males (n=1456) Females (n=898) p Value
Age (years) 61.4±7.7 61.1±8.1 61.8±7.0 0.030
Smoking n (%) 658 (28.0) 456 (31.5) 202 (22.7) <0.001
Alcohol (gr/week) 72.2±117.5 102.2±133.3 23.6±59.9 <0.001
Physical activity (METs-min/week) 2481±2512 2886±1831 1825±1691 <0.001
Sedentary n (%) 1020 (43.3) 538 (37.0) 482 (53.7) <0.001
Height (cm) 165±9 170±7 156±6 <0.001
Weight (kg) 79.4±14.6 83.9±13.4 72.2±13.3 <0.001
BMI (kg/m2) 29.2±4.4 29.1±3.9 29.5±5.1 0.035
BMI ≥30 n (%) 847 (36.0) 485 (33.4) 362 (40.4) 0.001
Waist circumference (cm) 100.9±11.6 102.9±10.5 97.6±12.5 <0.001
WHtR 0.61±0.07 0.61±0.06 0.62±0.08 <0.001
CUN-BAE 35.7±1.7 31.1±4.5 43.1±5.1 <0.001
BRI 5.8±1.7 5.7±1.5 6.1±2.1 <0.001
SBP (mm Hg) 137.1±17.4 138.9±17.1 134.2±17.5 <0.001
DBP (mm Hg) 84.4±10.2 85.5±10.4 82.7±9.7 <0.001
Heart rate (beats per minute) 74.2±10.2 73.3±12.7 75.8±11.6 <0.001
Hypertension n (%) 1712 (72.7) 1122 (80.1) 590 (75.4) <0.001
Antihypertensive drugs (n (%)) 1199 (50.9) 729 (50.2) 470 (52.6) 0.289
Total cholesterol (mg/dL) 225.8±40.9 220.8±39.1 233.9±42.5 <0.001
LDL cholesterol (mg/dL) 140.4±34.9 138.9±34.2 142.8±35.8 0.011
HDL cholesterol (mg/dL) 49.8±12.9 47.9±11.9 52.9±13.8 <0.001
Triglycerides (mg/dL) 145.5±96.6 150.3±106.3 137.7±77.9 0.001
Atherogenic index 4.8±1.3 4.8±1.3 4.7±1.3 0.002
Dyslipidaemia n ((%)) 2151 (91.4) 1311 (90.0) 840 (93.5) <0.001
Lipid lowering drugs (n (%)) 671 (28.5) 392 (26.8) 279 (31.0) 0.034
FPG (mg/dL) 107.2±34.8 106.9±33.9 107.6±36.1 0.659
HbA1c 4.8±1.3 5.9±1.4 6.1±1.4 0.001
Diabetes (n (%)) 791 (33.6) 463 (31.8) 328 (36.5) 0.020
Antidiabetic drugs (n (%)) 474 (20.1) 269 (18.5) 205 (22.9) 0.011
CAVI 8.8±1.2 8.9±1.2 8.6±1.1 <0.001
baPWV (m/s) 14.9±2.5 14.8±2.5 15.0±2.6 0.107
Values are means and (SD) for continuous data and number and (proportions) for categorical data.p Value differences between male and 
females.baPWV, brachuial-ankle pulse wave velocity; BMI, body mass index; BRI, body roundness index; CAVI, cardio-ankle vascular index; 
CUN-BAE, Clínica Universidad de Navarra-body adiposity estimator; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HbA1c, 
glycosylated haemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; METs-min/week, metabolic equivalent minutes per 
week; SBP, systolic blood pressure; WHtR, waist-to-height ratio.
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as a measure of stiffness. Some studies have described a 
greater association with measures of central or visceral 
adiposity in patients with diabetes and a general popu-
lation.3 13 17–19 21 However, Strasser et al62 found no asso-
ciation with BF%; other studies found no association 
between BMI and cfPWV.13 14 Rodrigues et al15 reported 
that BMI was negatively associated with cfPWV (β=−0.103) 
in a large cohort.
The Whitehall II Cohort study22 was completed based 
on staff lists from offices located in central London. It 
showed that all measures of adiposity were robust predic-
tors of accelerated cfPWV after adjusting for potential 
confounding factors. The use of different measures to 
evaluate arterial stiffness such as CAVI and baPWV—as 
well as the emphasis on a population with intermediate 
cardiovascular risk—could explain some of the discrep-
ancies with our study.
Arterial stiffness depends on arterial wall elasticity and 
diameter. A positive correlation was found between BMI 
and aortic diameter as measured by nuclear magnetic 
resonance.63 This could partially explain the negative 
association between measures of adiposity and arterial 
stiffness. The different results obtained here can be 
explained in part by different methods of arterial stiff-
ness measurements and the adjustment variables used. 
It might also be because CAVI is a measure of central 
and peripheral stiffness. In addition, the blood pres-
sure at the time of the measurement does not seem to 
modify its value.37 64 65 Conversely, the baPWV reflects 
peripheral arterial stiffness.38 Other influences poten-
tially underlying the observed differences are age, sex, 
race, prevalent cardiovascular diseases and drugs used 
for treatment of hypertension, diabetes mellitus and 
dyslipidaemia.12 51 59 61 These differences between CAVI 
and baPWV are measures of rigidity and could explain 
these results suggesting a greater association of adiposity 
measurements with CAVI than with baPWV.
The proportion of baPWV variability explained by 
adiposity measurements in our study was less than 1% 
(between 0.7% for BMI and 0.1% for CUN-BAE). The 
results are also lower than those published for the general 
population by Wohlfahrt et al (5% for WHtR and 3% for 
BMI)3 but are comparable with the results described by 
Rodrigues et al (BMI 0.7%).15 The proportion of CAVI 
variability explained by adiposity measures was higher 
than 5% with CUN-BAE and BMI and higher than 3.5% 
with WHtR and BRI. In the subgroup analysis, the propor-
tion of CAVI variability explained by adiposity measures 
was higher in diabetic, obese, younger, and non-hyper-
tensive subjects. Our results show that the influence of 
adiposity measurements on CAVI is greater than on 
baPWV. To the best of our knowledge, no other study has 
yet analysed this aspect using CAVI. The novel results of 
this study may have important clinical relevance because 
they show the associations of both general and abdom-
inal obesity measures with CAVI and baPWV in subjects 
with intermediate cardiovascular risk. Furthermore, the 
Table 2 Bivariate correlations of adiposity measures with 
CAVI and baPWV
CAVI baPWV
Unadjusted Adjusted† Unadjusted Adjusted†
BMI −0.264** −0.303** −0.035 −0.068**
WHtR −0.119** −0.222** 0.090** 0.001
CUN-BAE −0.187** −0.297** 0.054* −0.063**
BRI −0.125** −0.218** 0.078** 0.005
The correlation coefficients between CAVI, baPWV and 
adiposity measurements showed significant differences 
(p<0.001 in all cases).p Values by Pearson correlation: *p<0.05, 
**p<0.01.†Adjusted for age, sex and systolic blood pressure.
baPWV, brachial-ankle pulse wave velocity; BMI, body mass 
index; BRI, body roundness index; CAVI, cardio-ankle vascular 
index; CUN-BAE, Clínica Universidad de Navarra-body adiposity 
estimator; WHtR, waist-to-height ratio. 
Table 3 Multiple regression analysis: association between adiposity measures with CAVI and baPWV
R2 Standardised β No standardised β (95% CI) Partial R2 p Value
CAVI
BMI 0.412 −0.289 −0.075 (−0.083 to −0.066) 0.055 <0.001
WHtR 0.381 −0.221 −3.650 (−4.207 to −3.093) 0.038 <0.001
CUN-BAE 0.410 −0.450 −0.069 (−0.077 to −0.061) 0.058 <0.001
BRI 0.378 −0.215 −0.142 (−0.165 to −0.120) 0.037 <0.001
baPWV
BMI 0.402 −0.100 −0.057 (−0.076 to −0.038) 0.007 <0.001
WHtR 0.394 −0.044 −1.557 (−2.748 to −0.366) 0.001 0.021
CUN-BAE 0.401 −0.152 −0.050 (−0.068 to −0.033) 0.007 <0.001
BRI 0.394 −0.046 −0.066 (−0.115 to −0.018) 0.002 0.014
Four different multiple linear regression models were used to analyse the associations of adiposity measures with CAVI and baPWV.Adjusted 
for age (years), gender (0=male and 1=female), systolic blood pressure, smoking (0=no and 1=yes), atherogenic index, HbA1c and METs/
min/week.baPWV, brachial-ankle pulse wave velocity; BMI, body mass index; BRI, body roundness index; CAVI, cardio-ankle vascular index; 
CUN-BAE, Clínica Universidad de Navarra-body adiposity estimator; METs-min/week, metabolic equivalent min per week; WHtR, waist-to-
height ratio. 
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Table 4 Association between adiposity measures with CAVI in different groups
R2 β (95% CI) Partial R2 p Value
CAVI
Hypertensive
  BMI 0.409 −0.076 (−0.087 to −0.065) 0.023 <0.001
  WHtR 0.383 −3.838 (−4.527 to −3.148) 0.035 <0.001
  CUN-BAE 0.368 −0.068 (−0.078 to −0.058) 0.051 <0.001
  BRI 0.382 −0.165 (−0.193 to −0.137) 0.035 <0.001
Non-hypertensive
  BMI 0.372 −0.071 (−0.086 to −0.057) 0.052 <0.001
  WHtR 0.324 −2.939 (−3.850 to −2.028) 0.046 <0.001
  CUN-BAE 0.405 −0.065 (−0.080 to −0.052) 0.080 <0.001
  BRI 0.318 −0.108 (−0.144 to −0.072) 0.042 <0.001
Patients with diabetes
  BMI 0.439 −0.087 (−0.101 to −0.073) 0.95 <0.001
  WHtR 0.399 −4.613 (−5.523 to −3.702) 0.069 <0.001
  CUN-BAE 0.437 −0.083 (−0.096 to −0.070) 0.70 <0.001
  BRI 0.391 −0.169 (−0.205 to −0.134) 0.062 <0.001
Patients without diabetes
  BMI 0.396 −0.067 (−0.078 to −0.056) 0.049 <0.001
  WHtR 0.369 −3.088 (−3.781 to −2.396) 0.034 <0.001
  CUN-BAE 0.395 −0.059 (−0.069 to −0.050) 0.064 <0.001
  BRI 0.369 −0.130 (−0.159 to −0.099) 0.034 0.016
Obese
  BMI 0.414 −0.093 (−0.112 to −0.074) 0.054 <0.001
  WHtR 0.377 −2.945 (−4.085 to −1.804) 0.003 <0.001
  CUN-BAE 0.418 −0.100 (−0.122 to −0.079) 0.026 <0.001
  BRI 0.377 −0.110 (−0.153 to −0.069) 0.003 <0.001
Non-obese
  BMI 0.373 −0.058 (−0.078 to - 0.038) 0.013 <0.001
  WHtR 0.361 −1.394 (−2.366 to - 0.421) 0.003 0.005
  CUN-BAE 0.373 −0.050 (−0.066 to −0.033) 0.020 <0.001
  BRI 0.358 −0.044 (−0.085 to −0.003) 0.002 0.034
≤62 years
  BMI 0.368 −0.078 (−0.089 to −0.077) 0.77 0.003
  WHtR 0.332 −4.142 (−4.854 to −3.431) 0.065 <0.001
  CUN-BAE 0.361 −0.068 (−0.078 to −0.058) 0.070 <0.001
  BRI 0.324 −0.163 (−0.192 to −0.134) 0.062 <0.001
>62 years
  BMI 0.234 −0.074 (−0.088 to −0.060) 0.056 <0.001
  WHtR 0.195 −3.086 (−3.948 to −2.224) 0.029 <0.001
  CUN-BAE 0.234 −0.071 (−0.084 to −0.059) 0.065 <0.001
  BRI 0.193 −0.124 (−0.159 to −0.089) 0.028 <0.001
Assets
  BMI 0.414 −0.072 (−0.084 to −0.060) 0.053 <0.001
  WHtR 0.392 −3.570 (−4.335 to −2.805) 0.034 <0.001
  CUN-BAE 0.413 −0.066 (−0.075 to −0.053) 0.060 <0.001
Continued
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results provide information that could be used in new 
prospective studies and could potentially improve cardio-
vascular risk equations.
Various studies have analysed the effect of weight loss 
on arterial stiffness—most of these have been collected 
in two meta-analyses. The first analysed the results of 20 
studies (1259 participants) and showed that losses of 8% 
of the weight after making changes in the diet and in the 
lifestyles do diminish the PWV. Diet and lifestyle interven-
tions also seem to improve pulse wave velocity. The stan-
dardised mean difference (SMD) for the overall effect of 
weight loss on baPWV was −0.32 (p<0.001) cfPWV (SMD 
−0.35, p≤0.001) and baPWV (SMD −0.48, p<0.01); this 
improved with weight loss.66 In the second meta-analysis, 
43 studies (4231 participants) were included, and the 
average weight loss was 11% of the initial body weight; 
weight loss decreased CAVI (SMD=−0.48; p=0.04).67
In summary, our results show that the correlation 
between measures of adiposity and measures of arterial 
stiffness are greater with CAVI than with baPWV. The 
different measures of adiposity better explained the vari-
ability of arterial stiffness evaluated using CAVI than using 
baPWV. These suggest that the relationship with adiposity 
measures is greater if the arterial stiffness is measured 
using CAVI than with baPWV. This is likely because CAVI 
measures rigidity at the central and peripheral levels and 
is not affected by blood pressure at the time of measure-
ment.37 64 68 69
The most important limitation of this study is its trans-
versal design, which prevents the establishment of causal 
relationships as well as the direction of influence of 
adiposity measures on arterial stiffness. Another limita-
tion is that the population was ethnically homogeneous 
(all subjects were Caucasians with intermediate cardiovas-
cular risk). Therefore, the extrapolation of our findings 
may be limited.
COnCLusIOn
In conclusion, the adiposity measures analysed here show 
a negative association with arterial stiffness measures. 
The percentage of variation in CAVI that is explained by 
its relation to the different measures of adiposity ranges 
from 5.8% (CUN-BAE) to 3.7% (BRI). In the case of 
baPWV, it oscillates between 0.7% (CUN-BAE and BMI) 
and 0.1% (WHtR). These results suggest that measures of 
general adiposity and BF% better explain the variability 
of CAVI compared with measures of abdominal and 
visceral adiposity.
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